NRES Committee London - South East
Bristol Research Ethics Committee Centre
Level 3, Block B
Whitefriars,
Lewins Mead,
Bristol
BS1 2NT

Telephone: (0117) 3421382
Facsimile: (0117) 3420445

21 October 2013

Professor Philip M. W. Bath
Professor of Stroke Medicine
University of Nottingham
Division of Stroke Medicine - Research Dept
Clinical Sciences Building
City Hospital Campus
Hucknall Road
Nottingham
NG5 1PB

Dear Professor Bath

Study Title:	**Safety and tolerability of clopidogrel when added to aspirin and dipyridamole in high risk patients with recent ischaemic stroke: a randomised controlled trial**
REC reference:	**08/H1102/112**
Protocol number:	**31350**
EudraCT number:	**2007-006749-42**
Amendment number:	**SA/13/04**
Amendment date:	**09 October 2013**

Thank you for submitting the above amendment, which was received on 10 October 2013.

Research Site	
NHS Ayrshire & Arran, University Hospital, Ayr, Dalmellington Road	Dr Sandip Ghosh (Coordinating Investigator)
Craigavon Area Hospital, Southern Health & Social Care Trust, Portadown BT63 5QQ	Dr Michael McCormick (Principal Investigator)
North Cumbria Hospitals NHS Trust, West Cumberland, Whitehaven, Cumbria CA28 8JH	Dr E Olu Orugun (Principal Investigator at existing site)

The amendment relates solely to the addition of new site(s) and/or investigator(s) within the National Health Service (NHS) or Health and Social Care (HSC) in Northern Ireland. The

site-specific assessment for the site(s) will therefore form part of the research governance review. The Site-Specific Information (SSI) Form for the site should be included with the application for R&D approval.

On behalf of the Committee, I am pleased to confirm the extension of the favourable opinion to the new site(s) and/or investigator(s), subject to management permission being given by the relevant NHS/HSC R&D office(s) prior to the study starting at the site.

Statement of compliance

This Committee is recognised by the United Kingdom Ethics Committee Authority under the Medicines for Human Use (Clinical Trials) Regulations 2004, and is authorised to carry out the ethical review of clinical trials of investigational medicinal products.

The Committee is fully compliant with the Regulations as they relate to ethics committees and the conditions and principles of good clinical practice.

The Committee is constituted in accordance with the Governance Arrangements for Research Ethics Committees and complies fully with the Standard Operating Procedures for Research Ethics Committees in the UK.

08/H1102/112	**Please quote this number on all correspondence**

Yours sincerely



Mr Wai Yeung
REC Assistant

Email: nrescommittee.london-southeast@nhs.net

Copy to: *Mr Paul Cartledge*